Core Viewpoint - Shionogi & Co., Ltd. announced a $2.13 billion investment to acquire new shares in ViiV Healthcare, a company focused on HIV drug development, increasing its ownership stake to 21.7% [1][2]. Group 1: Transaction Details - Pfizer will divest its 11.7% stake in ViiV Healthcare for $1.88 billion, while GlaxoSmithKline (GSK) will receive a special dividend of $250 million as part of the agreement [1][2]. - After the transaction, GSK will retain a majority stake of 78.3% in ViiV Healthcare [1][2]. Group 2: Company Background - ViiV Healthcare is a joint venture established in 2009 between GSK and Pfizer, with Shionogi becoming a shareholder in 2012 [1][2]. - The company is currently focused on advancing long-acting injectable HIV treatment and prevention drugs [1][2].